Skip to content

Opiate Suicide Study in Patients with Major Depression

2019 Focus Grant
Amount Awarded: $1,416,096
Focus Areas: Neurobiological Studies, Clinical Treatment Studies

Alan Schatzberg, M.D.
Stanford University

Grant Information

There has been much effort to provide immediate relief to people during a suicidal crisis. Ketamine, a pain relief medicine, has been shown to rapidly reduce severe suicidal ideation. This study provides ketamine, followed by four weeks of treatment with placebo or buprenorphine (a medication used to treat opioid addiction and pain) in order to attempt to sustain the anti-suicidal effect over time.